AIDSWEEKLY Plus; Monday, September 28, 1998
Daniel J. DeNoon, Senior Editor
And as more U.S. patients buy more of the therapies - and thus live longer to buy even more - the market will keep growing for at least the rest of the decade, according to a new report by Datamonitor, a New York-based independent strategic management consultancy specializing in the analysis of global healthcare companies and their markets.
"The cost of maintaining patients using combination therapies will therefore increase as more people need the therapies longer," said Datamonitor analyst Patrick Taaffee. "Resistance to drugs is expected to become more of a problem in individual patients, and with increasing numbers of patients on combination therapies, cases of resistance will appear more frequently."
The Datamonitor report, "Market Dynamics: Global Opportunities in HIV to 2010," shows that the world market for AIDS therapies grew by 215 percent in 1996 and by a further 105 percent in 1997. The U.S. market was the major driver of this growth, the report indicated.
HIV protease inhibitors clearly are the basis for this rapid growth, although Glaxo's Combivir - a single pill combining the nucleoside reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT) and lamivudine (3TC) - has been a market leader in the first half of 1998.
The report predicts that market growth will be fastest in the remaining years of the 1990s, but that new growth will be fueled by demand for new drugs as patients develop resistance to existing medications.
For more information Datamonitor can be contacted at One Park Avenue, 14th Floor, New York, New York 10016-5802. Telephone: (212) 686-7400. Fax: (212) 686-2626. URL: <http://www.datamonitor.com>.
980928
AW980914
Copyright © 1998 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA.
Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsfile.com
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .